Liquid biopsy allows for the analysis of blood samples for tumour-related materials such as ctDNA and CTCs, aiding in the non-invasive monitoring of tumour progression.

The applications and opportunities offered by digital polymerase chain reaction (dPCR) technology have provided new techniques for molecular diagnostics. With an estimated global market value of USD $1bn by 2032, the future looks promising for dPCR approaches.

This month’s discussion was led by Pieter van der Velden. Topics included improving multiplex assays, T-Cell quantification and DNA methylation.

Explore the history of PCR and how digital droplet PCR is being used for COVID-19 research.

In this commentary article, we present Dr Valerie Taly’s insights on the latest research into digital droplet PCR and the potential applications of liquid biopsy in cancer detection.